Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001365:Axilla; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011897:Random Allocation; D011960:Receptors, Estrogen / Q000502:physiology*; D013629:Tamoxifen / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage
D011960:Receptors, Estrogen; D013629:Tamoxifen; D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate